A compound of one of the formulae IA, IB or IC wherein: R 1 is pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolopyridinyl, imidazopyridinyl or pyrazolopyridinyl, wherein each heterocycle is optionally independently substituted with one to three groups selected from Ra, Rb and Rc; R 2 is C 1 -C 6 alkyl or C 3-6 cycloalkyl optionally substituted with C 1-3 alkyl; R 3 is H, -OH, halogen, -CN, C 1-6 alkoxy, -COOR 8, -C NR 8 R 9 or 5-6 membered heteroaryl ring which is optionally substituted with C 1-3 alkyl; R 4, R 5, and R 6 are each independently selected from (a) -H, (b) -OH, (c) halogen, (d) -CN, (e) -CF 3, (f) C 1 - 6 alkyl optionally substituted with one to three -OH, fluorine, C 1-6 alkoxyl - N(R 8)(R 9), or -C N(R 8)(R 9), (g) C 3 - 6 cycloalkyl (h) C 1-6 alkoxy optionally substituted with one to three -OH, fluorine, -OC 1 - 6 alkyl, or -OC 3 - 6 cycloalkyl (i) -S n C 1-6 alkyl, (j) -S 2 aryl (k) -S 2 heterocycle (l) -CO 2 R 8, (m) -SCF 3, (n') a 5-6 membered heterocyclic ring; R 8 and R 9 are each independently selected from -H, C 1-6 alkyl, and 5-6 membered heterocyclic ring; Ra is selected from H, -NH 2, -NH(C 1 -C 6)alkyl, -NR 10 R 11, -NH-C C 1 -C 6 alkyl, NR 11 -C C 1 -C 6 alkyl, -O(C 1 -C 8)alkyl, -O(C 3 -C 6)cycloalkyl, -S-(C 1 -C 6)alkyl, -S -C 1 -C 6 alkyl, -S 2 - C 1 -C 6 alkyl, and -CH 2 -OH; Rb is selected from -H, -(C 1 -C 6)alkyl, -O-(C 1 -C 6)alkyl, -NH 2, -CH 2 -OH, -C≡N, - CH 2 NH 2 and -C OCH 3; Rc is selected from -H, -CH 3 and -OH; R 10 and R 11 are each independently selected from -H, C 1-6 alkyl, C 1-6 alkyl- 5-6 membered heterocyclyl, C 1-6 alkyl- 5-6 membered heteroaryl optionally substituted with halogen and C 1-6 alkyl- aryl; n is 0, 1 or 2; or a pharmaceutically acceptable salt thereof. R 1 is pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolopyridinyl, imidazopyridinyl or pyrazolopyridinyl, wherein each heterocycle is optionally independently substituted with one to three groups selected from Ra, Rb and Rc; R 2 is C 1 -C 6 alkyl or C 3-6 cycloalkyl optionally substituted with C 1-3 alkyl; R 3 is H, -OH, halogen, -CN, C 1-6 alkoxy, -COOR 8, -C NR 8 R 9 or 5-6 membered heteroaryl ring which is optionally substituted with C 1-3 alkyl; R 4, R 5, and R 6 are each independently selected from (a) -H, (b) -OH, (c) halogen, (d) -CN, (e) -CF 3, (f) C 1 - 6 alkyl optionally substituted with one to three -OH, fluorine, C 1-6 alkoxyl - N(R 8)(R 9), or -C N(R 8)(R 9), (g) C 3 - 6 cycloalkyl (h) C 1-6 alkoxy optionally substituted with one to three -OH, fluorine, -OC 1 - 6 alkyl, or -OC 3 - 6 cycloalkyl (i) -S n C 1-6 alkyl, (j) -S 2 aryl (k) -S 2 heterocycle (l) -CO 2 R 8, (m) -SCF 3, (n') a 5-6 membered heterocyclic ring; (a) -H, (b) -OH, (c) halogen, (d) -CN, (e) -CF 3, (f) C 1 - 6 alkyl optionally substituted with one to three -OH, fluorine, C 1-6 alkoxyl - N(R 8)(R 9), or -C N(R 8)(R 9), (g) C 3 - 6 cycloalkyl (h) C 1-6 alkoxy optionally substituted with one to three -OH, fluorine, -OC 1 - 6 alkyl, or -OC 3 - 6 cycloalkyl (i) -S n C 1-6 alkyl, (j) -S 2 aryl (k) -S 2 heterocycle (l) -CO 2 R 8, (m) -SCF 3, (n') a 5-6 membered heterocyclic ring; R 8 and R 9 are each independently selected from -H, C 1-6 alkyl, and 5-6 membered heterocyclic ring; Ra is selected from H, -NH 2, -NH(C 1 -C 6)alkyl, -NR 10 R 11, -NH-C C 1 -C 6 alkyl, NR 11 -C C 1 -C 6 alkyl, -O(C 1 -C 8)alkyl, -O(C 3 -C 6)cycloalkyl, -S-(C 1 -C 6)alkyl, -S -C 1 -C 6 alkyl, -S 2 - C 1 -C 6 alkyl, and -CH 2 -OH; Rb is selected from -H, -(C 1 -C 6)alkyl, -O-(C 1 -C 6)alkyl, -NH 2, -CH 2 -OH, -C≡N, - CH 2 NH 2 and -C OCH 3; Rc is selected from -H, -CH 3 and -OH; R 10 and R 11 are each independently selected from -H, C 1-6 alkyl, C 1-6 alkyl- 5-6 membered heterocyclyl, C 1-6 alkyl- 5-6 membered heteroaryl optionally substituted with halogen and C 1-6 alkyl- aryl; n is 0, 1 or 2; or a pharmaceutically acceptable salt thereof.